Metagenomi Therapeutics (MGX) Stock
Small biotech developing gene editing tools from microbes. Here's the price, business snapshot, and what's worth knowing about Metagenomi Therapeutics in August 2026.
Metagenomi Technologies, LLC (ticker MGX) is a small-cap biotechnology company (market capitalisation US$118.23m) focused on discovering and developing gene‑editing systems derived from microbial genomes. The firm seeks novel CRISPR-like enzymes and related tools that could be applied to therapeutics, research reagents or industrial biotechnology, with potential to be progressed internally or licenced to partners. As an early-stage life sciences company, Metagenomi typically carries higher scientific, regulatory and commercial risk than larger pharma peers; progress is often milestone-driven and funding needs can lead to dilution. Investors commonly monitor preclinical data, partnership announcements, licensing deals and regulatory milestones as indicators of progress. This summary is for educational purposes only and not personalised investment advice — returns are not guaranteed and the share price may be volatile. Consider your risk tolerance and seek independent advice or perform further due diligence before investing.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Metagenomi Technologies' stock with a target price of $19.8, indicating significant growth potential.
Financial Health
Metagenomi Technologies is performing well with strong revenue and cash flow, indicating solid financial stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Small-cap growth story
Early‑stage technology can offer upside if platforms validate, but small‑cap biotech stocks are typically volatile and fundraising may dilute shareholders.
Novel editing platforms
The company explores microbial‑derived gene‑editing systems that could be licenced or developed further, though scientific and regulatory hurdles remain.
Partnerships and deals
Collaborations or licensing agreements can de‑risk development and create revenue paths, yet progress depends on successful R&D and approvals.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
